TGFB1 and Hepatic fibrosis: Preclinical results showed that TGF-β inhibitor Galunisertib affected parenchymal cell fate by regulating the biochemical composition of deposited extracellular matrix and inhibited the progression of liver fibrosis, but did not significantly improve the pathological grading of fibrosis in Abcb4ko mice (185).